A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
NCT ID: NCT06584916
Last Updated: 2025-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
376 participants
INTERVENTIONAL
2024-09-13
2025-11-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Orforglipron
Participants will receive orforglipron orally
Orforglipron
Administered orally
Placebo
Participants will receive placebo orally
Placebo
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Orforglipron
Administered orally
Placebo
Administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Have a prior or planned surgical treatment for obesity
* Have acute or chronic hepatitis
* Have a history of acute or chronic pancreatitis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cahaba Research
Birmingham, Alabama, United States
Cahaba Research - Pelham
Pelham, Alabama, United States
Southern California Dermatology, Inc.
Santa Ana, California, United States
Encompass Clinical Research
Spring Valley, California, United States
University Clinical Investigators, Inc.
Tustin, California, United States
New Horizon Research Center
Miami, Florida, United States
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia, United States
Rocky Mountain Clinical Research
Idaho Falls, Idaho, United States
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
L-MARC Research Center
Louisville, Kentucky, United States
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, United States
Prime Health and Wellness/SKYCRNG
Fayette, Mississippi, United States
StudyMetrix Research
City of Saint Peters, Missouri, United States
Palm Research Center Tenaya
Las Vegas, Nevada, United States
Palm Research Center Sunset
Las Vegas, Nevada, United States
Weill Cornell Medical College
New York, New York, United States
PharmQuest Life Sciences, LLC
Greensboro, North Carolina, United States
Lillestol Research
Fargo, North Dakota, United States
Alliance for Multispecialty Research, LLC
Norman, Oklahoma, United States
Tribe Clinical Research, LLC
Greenville, South Carolina, United States
WR-Clinsearch, LLC
Chattanooga, Tennessee, United States
The University of Texas Health Science Center at Houston
Bellaire, Texas, United States
Velocity Clinical Research, Dallas
Dallas, Texas, United States
North Texas Endocrine Center
Dallas, Texas, United States
Biopharma Informatic, LLC
Houston, Texas, United States
PlanIt Research, PLLC
Houston, Texas, United States
Southern Endocrinology Associates
Mesquite, Texas, United States
Puerto Rico Medical Research
Ponce, , Puerto Rico
Wellness clinical Research Vega Baja
Vega Baja, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
27239
Identifier Type: -
Identifier Source: org_study_id
J2A-MC-GZPN
Identifier Type: OTHER
Identifier Source: secondary_id